Final efficacy and safety Results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study

Cesare Gridelli, Filippo De Marinis, Michael Thomas, Kumar Prabhash, Claude El Kouri, Fiona Blackhall, Frederique Bustin, Jean Louis Pujol, William J. John, Belen San Antonio, Annamaria Zimmermann, Nadia Chouaki, Carla Visseren-Grul, Luis G. Paz-Ares

Research output: Contribution to journalArticle

Abstract

Introduction: The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous non-small-cell lung cancer. Approximately 17% of patients receiving maintenance therapy in this study were 70 years of age or older. Here we report efficacy and safety Results from the PARAMOUNT study for elderly (70 years) and non-elderly (

Original languageEnglish
Pages (from-to)991-997
Number of pages7
JournalJournal of Thoracic Oncology
Volume9
Issue number7
DOIs
Publication statusPublished - 2014

Keywords

  • Elderly
  • Maintenance therapy
  • Non-small-cell lung cancer
  • Pemetrexed

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Final efficacy and safety Results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study'. Together they form a unique fingerprint.

  • Cite this

    Gridelli, C., De Marinis, F., Thomas, M., Prabhash, K., El Kouri, C., Blackhall, F., Bustin, F., Pujol, J. L., John, W. J., San Antonio, B., Zimmermann, A., Chouaki, N., Visseren-Grul, C., & Paz-Ares, L. G. (2014). Final efficacy and safety Results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. Journal of Thoracic Oncology, 9(7), 991-997. https://doi.org/10.1097/JTO.0000000000000207